

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**MTA Scope: Canagliflozin, dapagliflozin and empagliflozin  
monotherapy for treating type 2 diabetes**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
---

No equalities issues have been identified.
--

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
---

N/A
-----

3. Has any change to the draft scope been agreed to highlight potential equality issues?
--

N/A
-----

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues have been identified.

**Approved by Associate Director (name):** Janet Robertson

**Date:** 19/01/2015